Study Identifies Cholesterol Biosynthesis as Key Driver of Chemotherapy-Resistant Cancer Cells
Researchers using human tongue cancer organoids identified a subpopulation of 'cycling persister' (CP) cancer cells that continue proliferating during chemotherapy, linked to elevated cholesterol biosynthesis driven by the NR2F1 pathway. The study found that interferon and hypoxic signaling were suppressed in these resistant clones, while cholesterol production was distinctly elevated compared to non-persister cells. Blocking cholesterol biosynthesis with simvastatin significantly reduced the emergence of CP clones, pointing to a potential therapeutic target for preventing cancer relapse.
A preprint study posted to bioRxiv used time-lapse imaging of human tongue cancer organoids to track individual cancer cell clones during and after chemotherapy exposure, identifying a subpopulation called cycling persisters (CPs) that sustain proliferation even under drug treatment. CPs formed visibly larger clusters than non-CP clones, allowing researchers to physically separate thousands of each type from 3D organoid cultures for molecular analysis. Transcriptomic comparisons revealed that tumor-intrinsic interferon signaling and hypoxic pathways were inactivated in CPs, while the NR2F1-mediated cholesterol biosynthesis pathway was markedly upregulated. Treatment with simvastatin, a widely used cholesterol-lowering drug, significantly suppressed the appearance of CP clones, demonstrating a functional role for cholesterol biosynthesis in their emergence. The authors propose that clonal-level variation in these signaling pathways determines which individual tumor cells survive chemotherapy, offering new mechanistic insight into cancer relapse and identifying NR2F1-driven cholesterol biosynthesis as a candidate therapeutic target.
What's missing
As a preprint, this study has not yet undergone peer review. The research is conducted entirely in vitro using organoid models, and it is unclear whether the same CP mechanisms operate in vivo or in human patients. The study does not address whether simvastatin doses effective in organoids are clinically achievable or safe in a cancer treatment context, nor does it examine whether CP clones eventually drive relapse in animal models. The generalizability beyond tongue cancer to other tumor types also remains an open question.
What different sources said
- bioRxivCenter
Cycling persister clones with elevated NR2F1-mediated cholesterol biosynthesis cause chemotherapy resistance
Related
Gut Bacteria Enzyme Found to Break Down Heat-Processed Food Compounds, Producing Novel Biogenic Amines
Researchers have discovered that an enzyme in common gut bacteria can degrade N-epsilon-carboxymethyllysine (CML), a compound formed during thermal food processing, producing previously unknown biogenic amines. The enzyme, ornithine decarboxylase SpeC from enterobacteria, acts on CML and related modified lysine derivatives through a low-level 'underground' catalytic activity. This finding suggests a previously unrecognized communication axis between thermally processed dietary compounds and gut microbial physiology, with potential implications for host health.
Full-Length Gene Sequencing Reveals Two Distinct Bacterial Communities in Black-Legged Ticks Expanding Into Canada
Researchers used Oxford Nanopore full-length 16S rRNA gene sequencing to characterize the microbiome of Ixodes scapularis black-legged ticks collected in Nova Scotia, Canada, distinguishing between tick-adapted bacteria and environmentally acquired bacteria. The study comes as I. scapularis — the primary vector of Lyme disease — is rapidly expanding northward into Canada due to climate change. The findings suggest that environmentally derived bacteria in tick microbiomes are not mere contamination, which has implications for how tick microbiome data is collected and interpreted across surveillance studies.
Study Identifies Metabolic Link Between Cell Envelope Stress and Biofilm Formation in Bacteria
Researchers have discovered that the metabolite acetyl-CoA directly inhibits enzymes that degrade the bacterial signaling molecule c-di-GMP, connecting cell envelope biosynthesis stress to biofilm formation in Pseudomonas aeruginosa. The study found that sub-inhibitory concentrations of antibiotics targeting early peptidoglycan biosynthesis — but not other antibiotic classes — elevate c-di-GMP levels by reducing phosphodiesterase activity, with acetyl-CoA competing for the enzyme active site. Because the relevant enzyme domain is broadly conserved across bacterial species, this checkpoint mechanism may be widespread and could have implications for understanding antibiotic-induced biofilm responses.